These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28975816)

  • 1. July 2017 ENCALS statement on edaravone.
    Al-Chalabi A; Andersen PM; Chandran S; Chio A; Corcia P; Couratier P; Danielsson O; de Carvalho M; Desnuelle C; Grehl T; Grosskreutz J; Holmøy T; Ingre C; Karlsborg M; Kleveland G; Koch JC; Koritnik B; KuzmaKozakiewicz M; Laaksovirta H; Ludolph A; McDermott C; Meyer T; Mitre Ropero B; Mora Pardina J; Nygren I; Petri S; Povedano Panades M; Salachas F; Shaw P; Silani V; Staaf G; Svenstrup K; Talbot K; Tysnes OB; Van Damme P; van der Kooi A; Weber M; Weydt P; Wolf J; Hardiman O; van den Berg LH
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Nov; 18(7-8):471-474. PubMed ID: 28975816
    [No Abstract]   [Full Text] [Related]  

  • 2. Edaravone (Radicava) for ALS.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):180-182. PubMed ID: 29125592
    [No Abstract]   [Full Text] [Related]  

  • 3. Edaravone in ALS.
    Takahashi R
    Exp Neurol; 2009 Jun; 217(2):235-6. PubMed ID: 19285071
    [No Abstract]   [Full Text] [Related]  

  • 4. Edaravone and its clinical development for amyotrophic lateral sclerosis.
    Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):20-31. PubMed ID: 28872918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    EDARAVONE (MCI-186) ALS 16 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):11-19. PubMed ID: 28872917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.
    Sawada H
    Expert Opin Pharmacother; 2017 May; 18(7):735-738. PubMed ID: 28406335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.
    Kalin A; Medina-Paraiso E; Ishizaki K; Kim A; Zhang Y; Saita T; Wasaki M
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):71-79. PubMed ID: 28872919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective.
    Yeo CJJ; Simmons Z
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):167-172. PubMed ID: 29334251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    Takei K; Takahashi F; Liu S; Tsuda K; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):49-54. PubMed ID: 28872913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.
    Nagase M; Yamamoto Y; Miyazaki Y; Yoshino H
    Redox Rep; 2016 May; 21(3):104-12. PubMed ID: 26191780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.
    Takei K; Tsuda K; Takahashi F; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):64-70. PubMed ID: 28872916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What can we learn from the edaravone development program for ALS?
    Maragakis NJ
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):98-103. PubMed ID: 28872911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis.
    Takahashi F; Takei K; Tsuda K; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):32-39. PubMed ID: 28872914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
    Abe K; Itoyama Y; Sobue G; Tsuji S; Aoki M; Doyu M; Hamada C; Kondo K; Yoneoka T; Akimoto M; Yoshino H;
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Dec; 15(7-8):610-7. PubMed ID: 25286015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger.
    Aoki M; Warita H; Mizuno H; Suzuki N; Yuki S; Itoyama Y
    Brain Res; 2011 Mar; 1382():321-5. PubMed ID: 21276427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edaravone in acute ischemic stroke.
    Kitagawa Y
    Intern Med; 2006; 45(5):225-6. PubMed ID: 16595983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.